NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics IRVINE, Calif. & AMSTERDAM--Agendia®, Inc., a leader in precision oncology for breast cancer, Read More
Genomic Profiling with MammaPrint ® + BluePrint ® Identifies Aggressive Tumor Subtypes Driving Racial Survival Disparities in HR+/HER2– Early-Stage Breast Cancer
Multicenter study of over 1000 females with breast cancer, published in npj Breast Cancer, finds that genomic risk and molecular subtype, and not race, drives differential survival outcomes IRVINE, Calif., and AMSTERDAM — March Read More
Agendia Announces NCCN Guideline Update Recognizing MammaPrint to Guide Personalized Anthracycline Use in HR+/HER2- Early‑Stage Breast Cancer
Agendia Announces NCCN Guideline Update Recognizing MammaPrint to Guide Personalized Anthracycline Use in HR+/HER2- Early‑Stage Breast Cancer Update based on real-world evidence from the FLEX Study presented at the 2025 San Antonio Breast Cancer Read More
Newsroom
News, Stories & Breast Cancer Blog
Mapping Your Path: How Genomic Testing Can Personalize Your Breast Cancer Treatment Plan
Genomic testing can help personalize your breast cancer treatment plan by helping map a path ahead. When navigating a breast cancer diagnosis, it can feel like approaching one fork in the road after another. Read More
Test May Predict Breast Cancer Recurrence Risk, Chemotherapy Benefit
For patients with HR+, HER2- early breast cancer, MammaPrint may predict distant recurrence-free interval prognosis and chemotherapy benefit.Key TakeawaysMammaPrint effectively predicts chemotherapy benefit and distant recurrence-free interval in HR+HER2- early breast cancer.High-risk patients benefit significantly Read More
Understanding Predictive vs. Prognostic Breast Cancer Genomic Testing
What Does Your Breast Cancer Genomic Test Really Tell You— and Why MammaPrint’s Latest Data Matters? If you or someone you love has been diagnosed with early-stage breast cancer, especially HR-positive/ HER2-negative breast cancer, Read More
Genetic vs. Genomic Testing in Early-Stage Breast Cancer: What You Need to Know?
How these tests can help create a treatment plan that’s right for you Navigating Your Diagnosis Being diagnosed with early-stage breast cancer can feel overwhelming. You’re asked to make important decisions—often quickly—while trying to Read More
Agendia Named 2025 “Best Overall Genomics Company” By MedTech Breakthrough
Prestigious International Annual Awards Program Recognizes Standout Digital Health & Medical Technology Products and Companies MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global digital Read More
The Endocrine System and Breast Cancer Overview
The endocrine system is a series of glands responsible for creating and distributing hormones throughout the body, chemical messengers of sorts. This important system plays a role in many bodily functions, including regulating metabolism, Read More
Disparities in Breast Cancer Care, Genomic Insights and Early Detection
By Ryan Scott | March 19, 2025 Black women face a 40% higher mortality rate from breast cancer compared with other groups, according to the Breast Cancer Research Foundation, highlighting a disparity in detection, Read More
